Therapeutic applications of RNAi for silencing virus replication.

RNA interference (RNAi) is an evolutionarily conserved gene-silencing mechanism in which small 19-23-nucleotide double-stranded RNA molecules, or small interfering RNAs (siRNAs), target cognate RNA for destruction with exquisite potency and selectivity. The RNAi machinery is believed to be expressed in all eukaryotic cells and has been shown to regulate host gene expression. Given this ability, RNAi silencing strategies have been developed to inhibit viral genes and replication in host cells. One area of growing interest is the development of synthetic siRNA drugs to target acute viral infections in which long-term gene silencing is not required or desirable. To achieve synthetic siRNA drug efficacy, these anti-viral agents need to be delivered to the appropriate host cells, as they do not readily cross the cell membrane. Varied delivery and siRNA chemical stabilization strategies are being investigated for siRNA drug delivery; however, several studies have shown that naked, unmodified siRNA drugs can be effective in silencing replication of some viruses in animal models of infection. These findings suggest that RNAi-based drugs may offer breakthrough technology to protect and treat humans and animals from viral infection. However, there are four major considerations for evaluating successful RNAi efficacy: the siRNAs must have high efficiency, show low cytotoxicity, result in minimal off-target effects, and lead to results that are reproducible between experiments. The methods and caveats to achieve these goals are discussed.

[1]  J A Thomson,et al.  Short tandem repeat profiling provides an international reference standard for human cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Williams,et al.  RNA interference and double-stranded-RNA-activated pathways. , 2004, Biochemical Society transactions.

[3]  Norbert Perrimon,et al.  Drug-target identification in Drosophila cells: combining high-throughout RNAi and small-molecule screens. , 2007, Drug discovery today.

[4]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[5]  Stanley T. Crooke,et al.  Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells , 2007, Nucleic acids research.

[6]  C. T. Dann.  New technology for an old favorite: lentiviral transgenesis and RNAi in rats , 2007, Transgenic Research.

[7]  Michael T. McManus,et al.  RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[9]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[10]  H. Paulson,et al.  Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia , 2005, The Journal of Neuroscience.

[11]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[12]  Xiaoan Ruan,et al.  siRNA-mediated off-target gene silencing triggered by a 7 nt complementation , 2005, Nucleic acids research.

[13]  M. Amarzguioui,et al.  Approaches for chemically synthesized siRNA and vector‐mediated RNAi , 2005, FEBS letters.

[14]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[15]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[16]  Elisa Izaurralde,et al.  RNAi: finding the elusive endonuclease. , 2004, RNA.

[17]  N. Dean,et al.  Competition for RISC binding predicts in vitro potency of siRNA , 2006, Nucleic acids research.

[18]  K. Schmitt,et al.  Vector-based RNAi approaches for stable, inducible and genome-wide screens. , 2006, Drug discovery today.

[19]  A. Reynolds,et al.  A protocol for designing siRNAs with high functionality and specificity , 2007, Nature Protocols.

[20]  G. Arndt,et al.  Genome‐wide screening for gene function using RNAi in mammalian cells , 2005, Immunology and cell biology.

[21]  K. Kogure,et al.  A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. , 1996, Toxicon : official journal of the International Society on Toxinology.

[22]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.